LONDON (Reuters) – A new once-daily AIDS drug from GlaxoSmithKline and a partner Shionogi valid usually as good as Merck Co‘s twice-daily opposition Isentress in a late-stage clinical trial, boosting hopes for a product.
Both GSK’s new drug dolutegravir and Isentress are supposed integrase inhibitors, a novel category of drugs for fighting HIV/AIDS that retard a pathogen causing a illness from entering cells.
Dolutegravir is critical for GSK given it could assistance reinvigorate a HIV/AIDS business – an area of medicine it used to browbeat though where it has depressed behind rivals in new years.
GSK and Shionogi pronounced on Monday that their experimental drug dolutegravir showed non-inferiority to Isentress, or raltegravir, when given for 48 weeks alongside dual comparison forms of HIV/AIDS medicines.
In t...
0 comments
Post a Comment